Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos

This article was originally published in The Pink Sheet Daily

Executive Summary

AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.
Advertisement

Related Content

AMAG’s Feraheme Expansion Strategy Delayed For Now
Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans
People In The News: Changes At EnVivo, CSL, Biomed, Orexo, NCPA, And More
Business News, In Brief
Deals Of The Week: Spectrum/Allos, Amgen/AstraZeneca, Forest/Janssen
Spectrum Hopes For Synergies With Allos Acquisition Amid Phase III Setback
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011
Hedge Fund MSMB Offers to Buy AMAG For $381M and Thwart Proposed Allos Merger
Hedge Fund MSMB Offers to Buy AMAG For $381M and Thwart Proposed Allos Merger
Investors Balk At AMAG-Allos Proposed Marriage

Topics

Advertisement
UsernamePublicRestriction

Register

PS072924

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel